OCULOGENEX

Biotech · Private

Ocular gene therapy using novel delivery vehicles administered by retinal injection to treat dry age-related macular degeneration

Grants
$1.5M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
12
1 granted · 11 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Preclinical Validation of an Ocular Antioxidant Enhancing Gene Delivery Vehicle to Target Dry Macular Degeneration$256,000
Federal grantNational Science Foundation · Phase II · SBIR Phase II: Preclinical Validation of an Ocular Antioxidant Enhancing Gene Delivery Vehicle for Dry Macular Degeneration$1,199,722
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2182GIWOTECH INC.——
2183City Therapeutics——
2184CENNA BIOSCIENCES INC——
2185OCULOGENEX——
2186BIOSUPERIOR TECHNOLOGY INC——
2187NexImmune, Inc.—$35M
2188Platform Therapeutics, Inc.—$1.8M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 12
  • AAV-Mediated Gene Transfer for Retinopathyapplication
  • Microneedle Device For Intraocular Injections And Methods Of Using The Sameapplication
  • Aav-mediated Gene Transfer For Retinopathyapplication
  • AAV-Mediated Gene Transfer for Retinopathyapplication
  • AAV-mediated BMI1 gene transfer for treating macular degenerationgranted
  • Microneedle Device For Intraocular Injections And Methods Of Using The Sameapplication
  • Microneedle Device For Intraocular Injections And Methods Of Using The Sameapplication
  • Aav-mediated Gene Transfer For Retinopathyapplication
  • Aav-mediated Gene Transfer For Retinopathyapplication
  • Aav-mediated Gene Transfer For Retinopathyapplication
  • Microneedle Device For Intraocular Injections And Methods Of Using The Sameapplication
  • Aav-mediated Gene Transfer For Retinopathyapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.